GSK plc announced on August 27, 2024, that the Delaware Supreme Court will review a decision allowing expert evidence in the Zantac (ranitidine) litigation, asserting that 16 studies involving over 1 million patients show no reliable cancer risk from ranitidine. GSK is committed to defending itself vigorously during this litigation.